NKMax

Bio & Pharma NKMax to perform first tests on dementia cell therapy in US

NKMax Co., South Korea's largest developer of natural killer (NK) cell therapies, will conduct its first clinical trials in the US for its candidate...

Bio & Pharma NKMax's US subsidiary listed on Nasdaq

South Korean natural killer (NK) cell drugmaker NKMax Co. on Wednesday said its US subsidiary NKGen Biotech on Monday was listed on the Nasdaq Globa...

Bio & Pharma NKMax to supply health functional food to Chinese company

South Korean natural killer cell drug maker NKMax Co. announced in a regulatory filing on Friday that it has signed a supply contract with China's S...

Bio & Pharma NKMax submits US subsidiary's securities report to SEC

The listing in the US of NKGen Biotech, the American subsidiary of South Korean developer of natural killer (NK) cell therapy NKMax Co., is coming i...

Bio & Pharma S.Korean biotech NKMax’s unit aims for US IPO

NKMax Co., a South Korean cancer drug maker, is in talks with local and foreign investors in a bid to list its California-based unit NKGen Biotech I...